Abstract:KDM4A‐F enzymes are a subfamily of histone demethylases containing the Jumonji C domain (JmjC) using Fe(II) and 2‐oxoglutarate for their catalytic function. KDM4 enzymes are overexpressed or deregulated in cancer, thus leading to alteration in chromatin structure and transcriptional defects. As KDM4 enzymes have been associated with malignancy, they may represent novel targets for developing innovative therapeutic tools to treat different solid and blood tumors, of note, KDM4A is the isozyme most frequently associated with aggressive phenotypes of these tumors. To this aim, industrial and academic medicinal chemistry efforts have identified different KDM4 inhibitors. In most cases, these are pan‐KDM4 inhibitors, with low selectivity against other Jumonji family members. The pharmacophoric features of the inhibitors frequently include a chelating group capable of coordinating the catalytic iron within the active site of the KDM4 enzyme. Nonetheless, non‐chelating compounds have also demonstrated promising inhibitory activity, suggesting potential flexibility in the drug design. Several natural products, containing monovalent or bivalent chelators, have been identified as KDM4 inhibitors, albeit with a micromolar inhibition potency. This highlights the potential for leveraging them as templates for the design and synthesis of new derivatives, exploiting nature's chemical diversity to pursue more potent and selective KDM4 inhibitors.

Identification of the KDM2/7 Histone Lysine Demethylase Subfamily Inhibitor and Its Antiproliferative Activity.

Targeting N‐methyl‐lysine histone demethylase KDM4 in cancer: natural products inhibitors as a driving force for epigenetic drug discovery

Lysine-specific demethylase 7A (KDM7A): A potential target for disease therapy

Discovery of a Potent and Selective Inhibitor of Histone Lysine Demethylase KDM4D

Small Molecule KDM4s Inhibitors As Anti-Cancer Agents

Structural Simulation and Selective Inhibitor Discovery Study for Histone Demethylases KDM4E/6B from a Computational Perspective

Crystal structures of two inhibitors in complex with histone lysine demethylase 4D (KDM4D) provide new insights for rational drug design

An Inhibitor of KDM5 Demethylases Reduces Survival of Drug-Tolerant Cancer Cells.

Identification of potent, selective KDM5 inhibitors.

Targeting Histone Demethylase KDM5B for Cancer Treatment.

Pharmacological inhibition of KDM5A for cancer treatment

Targeting histone demethylase KDM5B for cancer treatment

Discovery of Pyrazole Derivatives As Cellular Active Inhibitors of Histone Lysine Specific Demethylase 5B (KDM5B/JARID1B).

Structure-Based identification of a potent KDM7A inhibitor exerts anticancer activity through transcriptionally reducing MKRN1 in taxol- resistant and -sensitive triple-negative breast cancer cells

Structure-guided design of a selective inhibitor of the methyltransferase KMT9 with cellular activity

Structure-Based Discovery of a Selective KDM5A Inhibitor that Exhibits Anti-Cancer Activity via Inducing Cell Cycle Arrest and Senescence in Breast Cancer Cell Lines

Design, Synthesis and Biological Evaluation of 4,6-Diarylquinoxaline-based KDM4D Inhibitors

Discovery of Pyrazolo[1,5-A]pyrimidine-3-carbonitrile Derivatives As a New Class of Histone Lysine Demethylase 4D (KDM4D) Inhibitors.

Biological Functions of the KDM2 Family of Histone Demethylases

Advances in Histone Demethylase KDM3A as a Cancer Therapeutic Target

KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease